Evidence map›Paper›PMID 23489628›Full record

ArticleBioorganic & medicinal chemistry letters2013

Identification and synthesis of N-(thiophen-2-yl) benzamide derivatives as BRAF(V600E) inhibitors.

Yunfeng Xie, Xianjie Chen, Jie Qin, Xiangqian Kong, Fei Ye, Yuren Jiang, Hong Liu, Hualiang Jiang, Ronen Marmorstein, Cheng Luo

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Yunfeng XieCollege of Chemistry and Chemical Engineering, Central South University, Changsha 410083, China.
Xianjie Chen
Jie Qin
Xiangqian Kong
Fei Ye
Yuren Jiang
Hong Liu
Hualiang Jiang
Ronen Marmorstein
Cheng Luo
Chinese Academy of Sciences · CNCentral South University · CNShanghai Institute of Materia Medica · CNThe Wistar Institute · USNanjing University · CN

Funding

Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1M
NCI NIH HHS P01 CA114046
6 · The paper itself

Abstract

The V600E BRAF kinase mutation, which activates the downstream MAPK signaling pathway, commonly occurs in about 8% of all human malignancies and about 50% of all melanomas. In this study, we employed virtual screening and chemical synthesis to identify a series of N-(thiophen-2-yl) benzamide derivatives as potent BRAF(V600E) inhibitors. Structure-activity relationship studies of these derivatives revealed that compounds b40 and b47 are the two most potent BRAF(V600E) inhibitors in this series.

Indexed as

BenzamidesCell ProliferationHumansMAP Kinase Signaling SystemModels, MolecularProto-Oncogene Proteins B-rafStructure-Activity RelationshipBenzamidesBRAF protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID23489628
PMCPMC4026330
OpenAlexW2076527999

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.